Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Resistance-Evading Antibiotic for Treating Anthrax.
Hughes D, Lawrence W, Peel J, Rosan W, Ling L, Niiti N, Aaron P, Shukla R, MacGillavry H, Heine H, Martha H, Elbert W, Weingarth M, Lewis K. Hughes D, et al. Among authors: aaron p. Res Sq [Preprint]. 2024 Mar 25:rs.3.rs-3991430. doi: 10.21203/rs.3.rs-3991430/v1. Res Sq. 2024. PMID: 38585816 Free PMC article. Preprint.
Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680].
Rocconi RP, Monk BJ, Walter A, Herzog TJ, Galanis E, Manning L, Bognar E, Wallraven G, Stanbery L, Aaron P, Senzer N, Coleman RL, Nemunaitis J. Rocconi RP, et al. Among authors: aaron p. Gynecol Oncol. 2023 Feb;169:173. doi: 10.1016/j.ygyno.2022.11.010. Epub 2022 Nov 28. Gynecol Oncol. 2023. PMID: 36456375 No abstract available.
Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy.
Sliheet E, Robinson M, Morand S, Choucair K, Willoughby D, Stanbery L, Aaron P, Bognar E, Nemunaitis J. Sliheet E, et al. Among authors: aaron p. Cancer Gene Ther. 2022 Jul;29(7):993-1000. doi: 10.1038/s41417-021-00400-x. Epub 2021 Nov 16. Cancer Gene Ther. 2022. PMID: 34785763 Free PMC article. Clinical Trial.
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
Walter A, Rocconi RP, Monk BJ, Herzog TJ, Manning L, Bognar E, Wallraven G, Aaron P, Horvath S, Tang M, Stanbery L, Coleman RL, Nemunaitis J. Walter A, et al. Among authors: aaron p. Gynecol Oncol. 2021 Dec;163(3):459-464. doi: 10.1016/j.ygyno.2021.10.004. Epub 2021 Oct 23. Gynecol Oncol. 2021. PMID: 34702567 Free article.
Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" [Gynecol. Oncol. Rep. 34 (2020) 100648].
Oh J, Barve M, Senzer N, Aaron P, Manning L, Wallraven G, Bognar E, Stanbery L, Horvath S, Manley M, Nemunaitis J, Walter A, Rocconi RP. Oh J, et al. Among authors: aaron p. Gynecol Oncol Rep. 2021 Mar 1;36:100740. doi: 10.1016/j.gore.2021.100740. eCollection 2021 May. Gynecol Oncol Rep. 2021. PMID: 34095420 Free PMC article.
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.
Rocconi RP, Stevens EE, Bottsford-Miller JN, Ghamande SA, Elder J, DeMars LL, Munkarah A, Aaron P, Stanbery L, Wallraven G, Bognar E, Manley M, Horvath S, Manning L, Walter A, Galanis E, Herzog T, Monk BJ, Coleman RL, Nemunaitis J. Rocconi RP, et al. Among authors: aaron p. Cancer Gene Ther. 2022 Mar;29(3-4):369-382. doi: 10.1038/s41417-021-00317-5. Epub 2021 Mar 22. Cancer Gene Ther. 2022. PMID: 33753870 Clinical Trial.
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
Rocconi RP, Monk BJ, Walter A, Herzog TJ, Galanis E, Manning L, Bognar E, Wallraven G, Stanbery L, Aaron P, Senzer N, Coleman RL, Nemunaitis J. Rocconi RP, et al. Among authors: aaron p. Gynecol Oncol. 2021 Jun;161(3):676-680. doi: 10.1016/j.ygyno.2021.03.009. Epub 2021 Mar 11. Gynecol Oncol. 2021. PMID: 33715892 Clinical Trial.
48 results